PAUL PERREAULT News & Analysis

And Morningstar analyst Nicolette Quinn has tempered her forecasts for sales of immunoglobulins.

Pharmaceutical giant CSL has lifted first-half profit 6.8 per cent to $US1.16bn ($1.63bn), helped by increased drug sales in the US.